MedPath

Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients

Phase 2
Completed
Conditions
Congestive Heart Failure
Registration Number
NCT00043758
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Brief Summary

The purpose of this study is to study the effects of tolvaptan on the size and function of the left heart chamber (ventricle) in patients with congestive heart failure (CHF)

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
170
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (40)

Desert Cardiology of Tucson

🇺🇸

Tucson, Arizona, United States

Arkansas Heart

🇺🇸

Little Rock, Arkansas, United States

San Diego Cardiac Center

🇺🇸

San Diego, California, United States

Northern California Medical Associates

🇺🇸

Santa Rosa, California, United States

Cardiovascular Consultants Medical Group, Inc.

🇺🇸

Walnut Creek, California, United States

University of Colorado

🇺🇸

Denver, Colorado, United States

The Hoffman Heart Institute of CT/St. Francis Hospital

🇺🇸

Hartford, Connecticut, United States

Yale University

🇺🇸

New Haven, Connecticut, United States

Cardiology Associates of Fort Lauderdale

🇺🇸

Fort Lauderdale, Florida, United States

Cardiovascular Research Center of South Florida

🇺🇸

Miami, Florida, United States

Scroll for more (30 remaining)
Desert Cardiology of Tucson
🇺🇸Tucson, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.